ARYx Therapeutics, Inc. Stock

ARYX

US0433871094

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 17:47:07 26/06/2023 +04			5-day change	1st Jan Change
0.001200 ^USD	+1,100.00%		-.--%	-

Valuation: ARYx Therapeutics, Inc.

Market Cap	9.03M 7.95M 7.38M 6.79M 12.73M 875M 12.96M 88.27M 34.43M 427M 33.92M 33.18M 1.48B	P/E 2008	-1.76x	P/E 2009	-2.66x
Enterprise Value	11.41M 10.03M 9.32M 8.57M 16.07M 1.1B 16.36M 111M 43.47M 539M 42.82M 41.89M 1.87B	EV / Sales 2008	4,019,605x	EV / Sales 2009	-
Free-Float	100%	Yield 2008 *	-	Yield 2009	-

* Estimated data More valuation ratios

Chart: ARYx Therapeutics, Inc.

Dynamic Chart

Press Releases: ARYx Therapeutics, Inc.

10/03/11	ARYX THER : ARYx Therapeutics Informed of Additional Delay by FDA and Begins Wind-Down of Operations	BU
24/12/10	ARYX THER : ARYx Therapeutics Clarifies Current Status of Operations	BU
21/12/10	ARYX THER : ARYx Therapeutics to Transfer to the NASDAQ Capital Market	BU
16/12/10	ARYX THER : ARYx Therapeutics Provides Update on Company Status	BU
15/11/10	ARYX THER : ARYx Therapeutics Reports Third Quarter Results	BU

More press releases

ARYx Therapeutics, Inc. is a United States-based pharmaceutical Company. The Company is developing a proprietary portfolio of patient-targeted, first-in-class monoclonal antibodies designed to treat seriously ill patients with difficult-to-treat diseases. It is engaged in retrometabolic drug design that focuses on the safety of oral therapies for chronic disease. The Companys clinical compounds include naronapride (ATI-7505) for gastrointestinal disorders; budiodarone (ATI-2042, for the treatment of atrial fibrillation; tecarfarin (ATI-5923) for the treatment of anticoagulation; and ATI-9242, for psychiatric disorders.

Employees

Sector

Biotechnology & Medical Research

More about the company

Stock Market
Stocks
ARYX Stock

As early as today, start finding the best investment opportunities!

5 years	0		0.04
10 years	0		0.05

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARYX THERAPEUTICS, INC.	+1,100.00%	-.--%	-	-.--%	33
WUXI APPTEC CO., LTD.	+1.23%	+0.35%	+51.62%	+87.98%	55.27B
ARGENX SE	+5.09%	+6.24%	+63.15%	+62.06%	54.15B
BIONTECH SE	+0.25%	+0.55%	-19.67%	-15.22%	23.22B
INSMED INCORPORATED	+0.72%	-0.05%	+3.84%	+409.54%	23.11B
WUXI BIOLOGICS (CAYMAN) INC.	-0.41%	+5.68%	+30.92%	-3.63%	20.33B
GENMAB A/S	-0.37%	+0.71%	+31.36%	-31.61%	17.91B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-0.77%	+6.29%	+33.32%	+547.87%	15.76B
PHARMAESSENTIA CORPORATION	-2.54%	-8.73%	+164.11%	+289.45%	15B
EXELIXIS, INC.	+1.22%	-0.05%	+22.58%	+182.63%	13.82B
Average	+110.43%	+0.64%	+42.36%	+152.91%	23.86B
Weighted average by Cap.	+1.33%	+2.77%	+43.56%	+134.95%

	2008	2009
Net sales	19.72 17.35 16.12 14.82 27.8 1.91K 28.29 192.71 75.17 931.67 74.05 72.45 3.23K	-
Net income	-31.22M -27.46M -25.51M -23.46M -43.99M -3.02B -44.78M -305M -119M -1.47B -117M -115M -5.12B	-33.17M -29.17M -27.1M -24.92M -46.74M -3.21B -47.58M -324M -126M -1.57B -125M -122M -5.44B
Net Debt	-29.9 -26.3 -24.43 -22.47 -42.14 -2.9K -42.9 -292.18 -113.96 -1.41K -112.27 -109.84 -4.9K	2.37 2.09 1.94 1.78 3.34 229.61 3.4 23.17 9.04 111.99 8.9 8.71 388.54

ARYx Therapeutics, Inc. Stock

Stocks

ARYX

US0433871094

Biotechnology & Medical Research

Valuation: ARYx Therapeutics, Inc.

Chart: ARYx Therapeutics, Inc.

Press Releases: ARYx Therapeutics, Inc.

Quotes and Performance

Course Extremes

Bio Therapeutic Drugs

Financials

Company Profile